Detalhe da pesquisa
1.
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial.
J Am Acad Dermatol
; 2024 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38556093
2.
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial.
J Am Acad Dermatol
; 90(5): 986-993, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38253129
3.
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.
Br J Dermatol
; 189(4): 392-399, 2023 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37279795
4.
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
JAMA
; 328(11): 1073-1084, 2022 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36125472
5.
A Phase 2 Open-Label Study to Evaluate VP-102 for the Treatment of Molluscum Contagiosum.
J Drugs Dermatol
; 20(1): 70-75, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33400412
6.
Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial.
Br J Dermatol
; 188(6): 810-812, 2023 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36890712
7.
Margins of freedom: a field-theoretic approach to class-based health dispositions and practices.
Sociol Health Illn
; 39(7): 1050-1067, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28332203
8.
The social dynamics of safe sex practices among Canadian sex industry clients.
Sociol Health Illn
; 38(6): 939-56, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27018404
9.
Towards a relational health promotion.
Health Promot Int
; 31(1): 209-13, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25080467
10.
A relational approach to health practices: towards transcending the agency-structure divide.
Sociol Health Illn
; 36(2): 187-98, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24443790
11.
When Patient Diversity Informs Formulation: Reimagining Treatment for Seborrheic Dermatitis.
Dermatol Ther (Heidelb)
; 2024 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38676839
12.
Quantification of skin lesions with a 3D stereovision camera system: validation and clinical applications.
Skin Res Technol
; 19(1): e182-90, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22716298
13.
Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies.
Am J Clin Dermatol
; 24(2): 315-324, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36422852
14.
IgE Depletion with Ligelizumab Does Not Significantly Improve Clinical Symptoms in Patients with Moderate-to-Severe Atopic Dermatitis.
J Invest Dermatol
; 143(10): 1896-1905.e8, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37004878
15.
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.
JAMA Dermatol
; 159(6): 613-620, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37133856
16.
Effects of New Zealand Blackcurrant Extract on Sequential Performance Testing in Male Rugby Union Players.
Sports (Basel)
; 10(10)2022 Oct 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36287765
17.
Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.
Oncologist
; 16(5): 543-53, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21490127
18.
Safety and Efficacy of VP-102 (Cantharidin, 0.7% w/v) in Molluscum Contagiosum by Body Region: Post hoc Pooled Analyses from Two Phase III Randomized Trials.
J Clin Aesthet Dermatol
; 14(10): 42-47, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34976290
19.
COVE-1: A Phase 2, Open-Label Study to Evaluate Efficacy and Safety and the Optimal Regimen of VP-102, a Proprietary Drug-Device Product Containing Topical Cantharidin (0.7% w/v) Under Occlusion for the Treatment of Common Warts.
Dermatol Ther (Heidelb)
; 11(5): 1623-1634, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34286459
20.
Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum.
Am J Clin Dermatol
; 22(2): 257-265, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33599960